• Acute lymphoblastic leukemia (ALL)
  • Hodgkin’s lymphoma
  • Non-Hodgkin’s lymphoma
  • Solid tumors

Dose:

  • Adults: IV 1.4 mg/m2/dose weekly
  • Children: IV 1.5-2mg/m2/dose weekly

 

  • Life-threatening infantile hemangioma (Off-label):
    • IV 0.05-1.5 mg/m2/dose *1 every 1-3 weeks for 3-4 doses

Injection: 1mg/mL

  • Prepare in IV infusion bags only
  • Dilute with infusion bags of 0.9% NaCl for a final concentration of 0.0015-0.08 mg/mL

Vinca alkaloid anticancer

It inhibits microtubule formation by acting on the M and S phase, arresting mitosis in metaphase

  • Alopecia
  • Constipation
  • Anorexia
  • Fatigue
  • Paresthesia
  • Peripheral neuropathy
  • Diarrhea
  • Dizziness
  • Hyperuricemia
  • Nausea
  • Vomiting
  • Urinary retention
  • Polyuria
  • Dysuria
  • BP changes
  • Oral ulcer
  • Hypersensitivity to class/components
  • Intrathecal use
  • Pregnancy 1st trimester
  • Demyelinating Charcot-Marie-Tooth disease
  • Breastfeeding during treatment and for at least 35 days after discontinuation

WARNING

  • Given only by individuals experienced with vincristine administration
  • For IV use only, fatal if given intrathecally
  • Vincristine extravasation during IV administration may cause considerable irritation, if extravasation occurs, immediately discontinue injection and give remaining dose via another vein
  • Bacterial live vaccines
  • Tamoligene

                          Drug Status

Availability Prescription only
Pregnancy Category D; Weigh risk vs benefit
Breastfeeding Contraindicated
Schedule Not controlled
BRAND NAME STRENGTH FORMULATION PACK SIZE MANUFACTURER DISTRIBUTOR
Biocristin-AQ 1mg/1mL Injection 1’s Zydus Healthcare Sai Pharma
Cipvin 1mg/1mL Injection 1’s Cipla Ltd Imperial Managed
Vistine 1mg Injection 1’s PSM Pharma PSM Pharma